Pancreatic Cancer's PD1-roadblock: When T-cell reinvigoration is not enough.

PD1-blockade combinations in PDAC have been poorly effective and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFkB signaling, which may limit productive tumor-controlling immunity.